VEEV Price Prediction Next Week
Technical Analysis: VEEV shows bearish signals with RSI at 43.60, indicating neutral to slightly oversold conditions. The stock is trading below its 5-day (230.11), 10-day (232.74), and 20-day (232.84) moving averages, suggesting short-term downward momentum. The MACD line (1.57) with negative histogram (-1.41) indicates weakening momentum.
Price Levels:
- Current price: $225.08
- Key resistance: $232.84 (20-day MA)
- Strong resistance: $245.79 (Upper Bollinger Band)
- Support: $219.89 (Lower Bollinger Band)
News Impact:
- Recent trading session showed weakness with -1.29% decline
- Tiger Global disclosed new investment in VEEV during Q4 2024, indicating institutional confidence
- Upcoming earnings report on March 5, 2025, with analysts expecting:
- EPS of $1.58 (+14.49% YoY)
- Revenue of $698.28M (+10.73% YoY)
Next Week Price Prediction: Based on technical indicators and upcoming catalysts:
- Bearish scenario (60% probability): Stock may test support at $219.89
- Neutral scenario (30% probability): Range-bound between $225-$232
- Bullish scenario (10% probability): Bounce toward $232.84 resistance
Target Price: $221.50 (-1.6% from current price)
Recommendation: SELL
- Technical indicators show bearish momentum
- Price trading below key moving averages
- RSI trending downward
- Upcoming earnings could increase volatility
VEEV Similar Chart Price Prediction
The price of VEEV is predicted to go up 0.48%, based on the high correlation periods with XBIT. The similarity of these two price pattern on the periods is 97.22%.
VEEV
XBIT
Up: 0.48%Similarity: 97.22%
VEEV Revenue Forecast
VEEV EPS Forecast
VEEV FAQs
What is bull’s view on VEEV?
What is bear's view on VEEV?
What is VEEV revenue forecast for next quarter？
What is VEEV eps forecast for next quarter？
VEEV VS S&P500
Veeva Vault continues to implement new products to its suite, which makes the offering even more attractive.
Focusing on new verticals like medical devices and diagnostics companies and consumer products and chemical industries opens up new end markets and opportunities.
Veeva's institutional knowledge and codevelopment partnerships with customers enable the company to develop robust offerings addressing market needs.
VEEV Analyst's Forecast
Gabriela Borges
Goldman Sachs
Strong Buy → Strong Sell
2025-01-23
Price Target
$261 → $200
Downside
-10.3%
Goldman Sachs analyst Gabriela Borges double-downgraded Veeva (VEEV) to Sell from Buy with a price target of $200, down from $261. The firm continues to view Veeva as significantly entrenched in its core Life Sciences customer base, with potential for cross sell over the next decade, though it also sees medium-term risks to the Street and Veeva's 2030 targets, the analyst tells investors in a research note. Veeva will remain the superior product relative to Salesforce (CRM), which is positioning for share gains, but competition will be an ongoing headwind for the stock, the firm adds, further noting that Veeva's product portfolio as a whole is maturing, making it challenging for newer product cycles such as CDMS to ramp materially enough to drive WholeCo acceleration.
Scott Schoenhaus
Keybanc
Buy
2025-01-08
Price Target
$285 → $255
Upside
+17.35%
Jeff Garro
Stephens & Co.
Buy
2024-12-20
Price Target
n/a
Downside
0%
